BioPharmics LLC is a leading brand in the field of computational drug design. Since its establishment in 1998, the company has focused on developing algorithms and software to revolutionize the process of drug discovery. Their comprehensive range of solutions includes innovative tools such as FGen3D, ForceGen, Surflex-Dock, eSim, QuanSA, and real-space modeling of ligand ensembles in X-ray density maps.

These cutting-edge methods combine physical realism in modeling protein-ligand interactions with rapid optimization algorithms for conformation and alignment of small molecules. One of BioPharmics' standout offerings is the Surflex Platform, which encompasses five fully integrated modules: Tools, Similarity, Docking, xGen, and Affinity. This platform provides a complete predictive modeling workflow, including 2D to 3D molecular conversion, accurate chirality interpretation, conformer elaboration for complex macrocycles, protein structure preparation and alignment, docking for pose prediction or virtual screening, and real-space modeling of ligands within X-ray density maps.

BioPharmics' software is compatible with Windows, Linux, and Mac platforms, enabling easy deployment across various devices, including workstations, laptops, and cloud-based resources. With their recent minor release, the company continues to uphold its commitment to innovation, delivering bug fixes, improvements, and added commands to enhance user experience. BioPharmics LLC is dedicated to pushing the boundaries of computational drug discovery, offering state-of-the-art solutions that optimize the efficiency and accuracy of the drug design process.

Their expertise and commitment to excellence have solidified their position as a trusted partner in the pharmaceutical industry. For more information, visit their website or reach out to them via email at info@biopharmics. com.

Stay updated with their latest developments by following them on Twitter, @biopharmics